{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:16:37Z","timestamp":1780877797655,"version":"3.54.1"},"reference-count":58,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2005,7,24]],"date-time":"2005-07-24T00:00:00Z","timestamp":1122163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>For the vast majority of patients with gastro\u2010oesophageal reflux disease appropriate care involves the management of symptoms with lifestyle advice and drugs. However, there is dissension about the appropriate use of endoscopy, whether drugs should be stepped up or down according to potency, how long drugs should be used for, the role of lifestyle advice, and, related to this, the role of patients\u2019 lifestyle choices.<\/jats:p><jats:p>This exploration of the economics of gastro\u2010oesophageal reflux disease reviews its cost burden to the UK, assesses published economic models for their strengths and weaknesses and examines current recommendations for gastro\u2010oesophageal reflux disease management from a socioeconomic perspective. Drugs prescribed predominantly for dyspepsia cost the UK National Health Service a projected \u00a3625\u2003million in 2004, 7% of the primary care prescribing budget. When general practitioners consultations, endoscopies, over\u2010the\u2010counter sales and sickness absences are included the UK cost rises to \u00a31.5\u2003billion: approximately half of this cost can be ascribed to gastro\u2010oesophageal reflux disease. Emphasis upon regular review and stepping down treatment (while maintaining adequate symptom relief) is both clinically appropriate and resource efficient. Other cost\u2010effectiveness issues largely lack objective answers because investment in treatment for gastro\u2010oesophageal reflux disease depends upon how much more, at the margin, society wishes to invest for further but diminishing symptom relief.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02606.x","type":"journal-article","created":{"date-parts":[[2005,7,24]],"date-time":"2005-07-24T22:52:58Z","timestamp":1122245578000},"page":"20-31","source":"Crossref","is-referenced-by-count":34,"title":["Review article: gastro\u2010oesophageal reflux disease \u2013 the health economic implications"],"prefix":"10.1111","volume":"22","author":[{"given":"J.","family":"MASON","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P. S.","family":"HUNGIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,7,24]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"576","article-title":"Management of dyspepsia: report of a working party","volume":"1","author":"Anonymous","year":"1988","journal-title":"Lancet"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/11024159850191184"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii37"},{"key":"e_1_2_7_5_2","volume-title":"Dyspepsia: Managing Dyspepsia in Adults in Primary Care. Centre for Health Services Research, Report No. 112","author":"North of England Dyspepsia Guideline Development Group","year":"2004"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.44.2008.S1"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.8.946"},{"key":"e_1_2_7_8_2","first-page":"160","article-title":"The symptoms sensitivity index: a valuable additional parameter in 24\u2003hour esophageal pH recording","volume":"86","author":"Breumelhof R","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.4.457"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.5.587"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.31.4.401"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90162-X"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.3.3.341"},{"key":"e_1_2_7_14_2","volume-title":"Hospital Episode Statistics 1994\u201395","author":"Department of Health","year":"1996"},{"key":"e_1_2_7_15_2","first-page":"93","article-title":"Endoscopic evaluation of gastro\u2010esophageal reflux disease","volume":"72","author":"Armstrong D","year":"1999","journal-title":"Yale J Biol Med"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.36.3.462"},{"key":"e_1_2_7_17_2","first-page":"536","article-title":"Endoscopy in primary care \u2013 a survey of current practice","volume":"52","author":"Galloway JM","year":"2002","journal-title":"Br J Gen Pract"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01303.x"},{"key":"e_1_2_7_19_2","author":"Department of Health","journal-title":"Prescription Cost Analysis: England 1998\u20132003"},{"key":"e_1_2_7_20_2","volume-title":"Morbidity Statistics from General Practice","author":"McCormick A","year":"1995"},{"key":"e_1_2_7_21_2","volume-title":"Unit Costs of Health and Social Care 2004","author":"Curtis L","year":"2004"},{"key":"e_1_2_7_22_2","author":"Department of Health","journal-title":"Reference Costs: England 1998\u20132003"},{"key":"e_1_2_7_23_2","volume-title":"Consultant Physicians Working for Patients. The Duties, Responsibilities and Practice of Physicians","author":"Royal College of Physicians","year":"2001"},{"key":"e_1_2_7_24_2","first-page":"1","article-title":"Healthy expansion of gastroenterology posts in England and Wales","volume":"8","author":"McIntyre A","year":"2000","journal-title":"BSG News"},{"key":"e_1_2_7_25_2","first-page":"167","article-title":"A comparison of workloads of physician\u2010gastroenterologists and other consultant physicians. Prepared on behalf of the Clinical Services Committee, British Society of Gastroenterology","volume":"26","author":"Smith PM","year":"1992","journal-title":"J R Coll Physicians Lond"},{"key":"e_1_2_7_26_2","volume-title":"Gastro\u2010intestinal Remedies","author":"Mintel International Group Limited","year":"2002"},{"key":"e_1_2_7_27_2","volume-title":"Gastro\u2010intestinal Remedies","author":"Mintel International Group Limited","year":"2004"},{"key":"e_1_2_7_28_2","volume-title":"National Statistics Feature: Trends and Sources of Data on Sickness Absence 2002","author":"Barham C","year":"2002"},{"key":"e_1_2_7_29_2","volume-title":"Labour Force Survey: Summary of Labour Market Structure \u2013 Aged 16+ (SA)","author":"Office for National Statistics","year":"2004"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.suppl_4.iv10"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02236-4"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200220050-00006"},{"key":"e_1_2_7_33_2","author":"World Health Organisation","journal-title":"Purchasing Power Parities 1995\u20132000"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529309098347"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00301-4"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01759.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01167.x"},{"key":"e_1_2_7_38_2","first-page":"657","article-title":"Probabilistic analysis of cost\u2010effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease","volume":"20","author":"Briggs AH","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199916060-00007"},{"key":"e_1_2_7_40_2","volume-title":"Proton Pump Inhibitors: Perspectives of Patients and their GPs","author":"Pollock K","year":"1998"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/146642400212200114"},{"key":"e_1_2_7_42_2","first-page":"703","article-title":"Proton pump inhibitors: perspectives of patients and their GPs","volume":"51","author":"Grime JC","year":"2001","journal-title":"Br J Gen Pract"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(00)00114-3"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01588.x"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00564.x"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00943.x"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200208000-00008"},{"key":"e_1_2_7_48_2","first-page":"A137","article-title":"Efficacy of lansoprazole on demand therapy in the treatment of non\u2010erosive reflux disease and functional ulcer\u2010like dyspepsia","volume":"52","author":"Cooper AL","year":"2003","journal-title":"Gut"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)81142-3"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)82724-5"},{"key":"e_1_2_7_51_2","article-title":"Esomeprazole 20\u2003mg on demand is more acceptable to patients than continuous lansoprazole 15\u2003mg in the long\u2010term maintenance of endoscopy\u2010negative gastro\u2010oeosphageal reflux patients: the COMMAND Study 2003","author":"Tsai H","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)81152-6"},{"key":"e_1_2_7_53_2","first-page":"A128","article-title":"Efficacy of continued and \u2018on demand\u2019 regimens lf pantoprazole 20\u2003mg in mild gastroesophageal reflux disease (abstract)","volume":"52","author":"Lacevic N","year":"2003","journal-title":"Gut"},{"key":"e_1_2_7_54_2","first-page":"A130","article-title":"Esomeprazole continuous versus on demand maintenance therapy in 1052 gastro\u2010oesophageal reflux disease patients: similar satisfaction but superior quality of life for once daily treatment (abstract)","volume":"52","author":"Engels LGJB","year":"2003","journal-title":"Gut"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365520212499"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00384.x"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7182.502"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02093.x"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01916.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02606.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02606.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T01:54:00Z","timestamp":1695779640000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02606.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,24]]},"references-count":58,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02606.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02606.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,24]]}}}